Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113


Antiviral activity and increased host defense against influenza infection elicited by the human cathelicidin LL-37.

Barlow PG, Svoboda P, Mackellar A, Nash AA, York IA, Pohl J, Davidson DJ, Donis RO.

PLoS One. 2011;6(10):e25333. doi: 10.1371/journal.pone.0025333. Epub 2011 Oct 21.


Human cathelicidin LL-37-derived peptide IG-19 confers protection in a murine model of collagen-induced arthritis.

Chow LN, Choi KY, Piyadasa H, Bossert M, Uzonna J, Klonisch T, Mookherjee N.

Mol Immunol. 2014 Feb;57(2):86-92. doi: 10.1016/j.molimm.2013.08.011. Epub 2013 Oct 1.


Cationic host defense peptides; novel antimicrobial therapeutics against Category A pathogens and emerging infections.

Findlay F, Proudfoot L, Stevens C, Barlow PG.

Pathog Glob Health. 2016 Jun-Jul;110(4-5):137-47. doi: 10.1080/20477724.2016.1195036. Epub 2016 Jun 17. Review.


Cathelicidins Have Direct Antiviral Activity against Respiratory Syncytial Virus In Vitro and Protective Function In Vivo in Mice and Humans.

Currie SM, Gwyer Findlay E, McFarlane AJ, Fitch PM, Böttcher B, Colegrave N, Paras A, Jozwik A, Chiu C, Schwarze J, Davidson DJ.

J Immunol. 2016 Mar 15;196(6):2699-710. doi: 10.4049/jimmunol.1502478. Epub 2016 Feb 12.


Cathelicidins display conserved direct antiviral activity towards rhinovirus.

Sousa FH, Casanova V, Findlay F, Stevens C, Svoboda P, Pohl J, Proudfoot L, Barlow PG.

Peptides. 2017 Sep;95:76-83. doi: 10.1016/j.peptides.2017.07.013. Epub 2017 Jul 29.


The human cathelicidin LL-37 has antiviral activity against respiratory syncytial virus.

Currie SM, Findlay EG, McHugh BJ, Mackellar A, Man T, Macmillan D, Wang H, Fitch PM, Schwarze J, Davidson DJ.

PLoS One. 2013 Aug 30;8(8):e73659. doi: 10.1371/journal.pone.0073659. eCollection 2013.


Antimicrobial peptides alter early immune response to influenza A virus infection in C57BL/6 mice.

LeMessurier KS, Lin Y, McCullers JA, Samarasinghe AE.

Antiviral Res. 2016 Sep;133:208-17. doi: 10.1016/j.antiviral.2016.08.013. Epub 2016 Aug 13.


The human cathelicidin LL-37 inhibits influenza A viruses through a mechanism distinct from that of surfactant protein D or defensins.

Tripathi S, Tecle T, Verma A, Crouch E, White M, Hartshorn KL.

J Gen Virol. 2013 Jan;94(Pt 1):40-9. doi: 10.1099/vir.0.045013-0. Epub 2012 Oct 10.


Cathelicidin deficiency predisposes to eczema herpeticum.

Howell MD, Wollenberg A, Gallo RL, Flaig M, Streib JE, Wong C, Pavicic T, Boguniewicz M, Leung DY.

J Allergy Clin Immunol. 2006 Apr;117(4):836-41. Epub 2006 Feb 14.


Quelling the storm: utilization of sphingosine-1-phosphate receptor signaling to ameliorate influenza virus-induced cytokine storm.

Walsh KB, Teijaro JR, Rosen H, Oldstone MB.

Immunol Res. 2011 Oct;51(1):15-25. doi: 10.1007/s12026-011-8240-z. Review.


Saikosaponin A inhibits influenza A virus replication and lung immunopathology.

Chen J, Duan M, Zhao Y, Ling F, Xiao K, Li Q, Li B, Lu C, Qi W, Zeng Z, Liao M, Liu Y, Chen W.

Oncotarget. 2015 Dec 15;6(40):42541-56. doi: 10.18632/oncotarget.6448.


Inhibitory influence of the hexapeptidic sequence SLIGRL on influenza A virus infection in mice.

Betts RJ, Mann TS, Henry PJ.

J Pharmacol Exp Ther. 2012 Dec;343(3):725-35. doi: 10.1124/jpet.112.196485. Epub 2012 Sep 17.


Unique features of human cathelicidin LL-37.

Bandurska K, Berdowska A, Barczyńska-Felusiak R, Krupa P.

Biofactors. 2015 Sep-Oct;41(5):289-300. doi: 10.1002/biof.1225. Epub 2015 Oct 5. Review.


The Flavonoid Isoliquiritigenin Reduces Lung Inflammation and Mouse Morbidity during Influenza Virus Infection.

Traboulsi H, Cloutier A, Boyapelly K, Bonin MA, Marsault É, Cantin AM, Richter MV.

Antimicrob Agents Chemother. 2015 Oct;59(10):6317-27. doi: 10.1128/AAC.01098-15. Epub 2015 Jul 27.


A zanamivir dimer with prophylactic and enhanced therapeutic activity against influenza viruses.

Tarbet EB, Hamilton S, Vollmer AH, Luttick A, Ng WC, Pryor M, Hurst BL, Crawford S, Smee DF, Tucker SP.

J Antimicrob Chemother. 2014 Aug;69(8):2164-74. doi: 10.1093/jac/dku127. Epub 2014 Apr 28.


Therapeutic activity of an anti-idiotypic antibody-derived killer peptide against influenza A virus experimental infection.

Conti G, Magliani W, Conti S, Nencioni L, Sgarbanti R, Palamara AT, Polonelli L.

Antimicrob Agents Chemother. 2008 Dec;52(12):4331-7. doi: 10.1128/AAC.00506-08. Epub 2008 Sep 29.


Cathelicidin host defence peptide augments clearance of pulmonary Pseudomonas aeruginosa infection by its influence on neutrophil function in vivo.

Beaumont PE, McHugh B, Gwyer Findlay E, Mackellar A, Mackenzie KJ, Gallo RL, Govan JR, Simpson AJ, Davidson DJ.

PLoS One. 2014 Jun 2;9(6):e99029. doi: 10.1371/journal.pone.0099029. eCollection 2014.


In vitro and in vivo efficacy of fluorodeoxycytidine analogs against highly pathogenic avian influenza H5N1, seasonal, and pandemic H1N1 virus infections.

Kumaki Y, Day CW, Smee DF, Morrey JD, Barnard DL.

Antiviral Res. 2011 Nov;92(2):329-40. doi: 10.1016/j.antiviral.2011.09.001. Epub 2011 Sep 8.

Supplemental Content

Support Center